Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence : Episode 5
Leveraging Real-World Evidence in Sequencing Decisions for mCRC
Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
Now Viewing
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
EP: 11.Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
EP: 12.Enhancing Support and Care Coordination in mCRC
Panelists explain that in the absence of head-to-head trial data, real-world evidence (RWE) becomes crucial in guiding sequencing decisions between agents such as trifluridine/tipiracil, fruquintinib, and regorafenib.
They highlight how RWE provides insights into treatment outcomes across broader and more diverse patient populations than those typically seen in clinical trials.
This information allows clinicians to refine sequencing strategies, especially when balancing efficacy and tolerability for patients in later-line settings.
Related Videos
Related Content
